Skip to content

Dr. Gearóid Tuohy

Genentech (Roche) has announced a voluntarily manufacturing recall for their implant (Port Delivery System with ranibizumab, “Susvimo”) to treat neovascular age-related macular degeneration (nAMD)

Genentech (Roche) has announced a voluntarily recall of the “Susvimo” (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. The… Read More »Genentech (Roche) has announced a voluntarily manufacturing recall for their implant (Port Delivery System with ranibizumab, “Susvimo”) to treat neovascular age-related macular degeneration (nAMD)

Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported the completion of enrollment for a Phase 2 study for Stargardt disease.  The study… Read More »Nanoscope Therapeutics Inc., have announced the completion of enrolment for Phase 2 Stargardt disease study with optogenetic gene therapy 

EURETINA Hamburg 2022: Spanish researchers report that hair cortisol level may be used as a molecular biomarker in retinitis pigmentosa patients

Researchers at the Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Spain, has reported results on the use of hair cortisol concentrations (HCC), measuring chronic… Read More »EURETINA Hamburg 2022: Spanish researchers report that hair cortisol level may be used as a molecular biomarker in retinitis pigmentosa patients

The Coimbra Eye Study has identified phenotypic differences between carriers and non-carriers of rare variants of the CFH gene

Researchers at the Coimbra Institute for Clinical and Biomedical Research, University of Coimbra, Portugal, have reported a clear association between rare genetic variants in complement… Read More »The Coimbra Eye Study has identified phenotypic differences between carriers and non-carriers of rare variants of the CFH gene

Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).

Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced approval of CIMERLI (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection) for all five indications  – for… Read More »Coherus BioSciences, Inc. (NASDAQ: CHRS), has announced the approval of “CIMERL” a biosimilar interchangeable to Lucentis for all five indications (AMD, RVO, DME, DR and mCNV).